If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.50    2.50 (0.64%)
Bid:
385.00
Ask:
400.00
Spread: 15.00 (3.896%)
Market Cap: £188.39m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

CFO succession planning

15 May 2025 07:00

RNS Number : 7165I
Tristel PLC
15 May 2025
 

TRISTEL plc

("Tristel" or the "Company" or the "Group")

 

CFO succession planning

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Liz Dixon, Chief Financial Officer ("CFO"), has confirmed to the Board her intention to retire from the business on 30 June 2025.

 

A process to appoint a new CFO is well underway and the Board has been pleased with the quality of candidates showing an interest in the position. A further announcement will be made in due course.

 

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the Company I would like to offer my thanks to Liz for her contribution to the business over the years. Liz has been involved with Tristel since July 2007 when she joined as Group Chief Accountant, before becoming Finance Director of our main trading subsidiary in August 2009, and ultimately joining the Board in June 2010. She played a critical role in securing market access to North America and has positioned Tristel very well for continued profitable growth."

 

Matt Sassone, Chief Executive Officer of Tristel, commented: "Since Liz joined Tristel, the company has grown considerably, and Liz has played a pivotal role in that success. In addition to supporting the operational side of the business, she has been instrumental in driving our commercial performance and built a robust, capable finance team-ensuring we are well-positioned for the continued expansion we anticipate in the years ahead.

 

"It has been a pleasure to work with Liz over the last nine months, and I am grateful that due to her stewardship I have joined a business with a very strong financial position, and well-funded to deliver further organic commercial growth."

 

Liz Dixon, Chief Financial Officer of Tristel, commented: "Whilst I am very sad to be leaving Tristel after nearly 18 years, I do so happy in the knowledge that the business is well placed both financially and commercially for its next stage of growth under the leadership of Matt and the senior team.

 

"It has been a great pleasure to have been part of an amazing UK success story, and to see Tristel establish a leading position in the global infection prevention world. I wish the incredible Tristel team the very best and am confident that they will continue to deliver to our shareholders."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Alice Woodings 

Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFFREIISLIE
Date   Source Headline
2nd Dec 20202:00 pmRNSUpdate to Executive Performance Share Plan 2021
2nd Dec 202010:30 amRNSTristel wins AIM Growth Business of the Year Award
9th Nov 20209:49 amRNSExercise of Options
2nd Nov 202010:30 amRNSQ&A update following preliminary results
27th Oct 20204:50 pmRNSIssue of Equity
19th Oct 20203:15 pmRNSDividend Timetable
19th Oct 20207:00 amRNSFinal Results
6th Oct 20207:00 amRNSNotice of Results
5th Oct 20204:41 pmRNSIssue of Equity
2nd Oct 20209:11 amRNSIssue of Equity
7th Sep 20201:16 pmRNSIssue of Equity
21st Aug 20207:00 amRNSTristel’s Duo for Ultrasound approved in India
7th Aug 202010:46 amRNSIssue of Equity
6th Aug 202010:30 amRNSUpdate from Virtual Shareholder Open Day
22nd Jul 20204:43 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Jul 20209:05 amRNSSecond Price Monitoring Extn
22nd Jul 20209:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSTrading update
23rd Jun 20207:00 amRNSNotice of Trading update, Results & presentation
8th Jun 202010:40 amRNSIssue of Equity
22nd May 20209:47 amRNSIssue of Equity
28th Apr 20203:40 pmRNSIssue of Equity
27th Apr 20207:00 amRNSDirector Appointment
14th Apr 202010:02 amRNSIssue of Equity
7th Apr 202010:38 amRNSIssue of Equity
31st Mar 20208:00 amRNSHolding(s) in Company
25th Mar 202012:38 pmRNSHolding(s) in Company
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:00 amRNSLicense & Product Supply Agreement with Byotrol
20th Mar 20204:43 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:37 pmRNSPrice Monitoring Extension
13th Mar 20204:14 pmRNSIssue of Equity
10th Mar 202011:56 amRNSIssue of Equity
6th Mar 20201:42 pmRNSHolding(s) in Company
3rd Mar 202010:24 amRNSDirector/PDMR Shareholding and Issue of Equity
26th Feb 20207:00 amRNSHolding(s) in Company
25th Feb 20209:06 amRNSDirector/PDMR Shareholding (Replacement)
25th Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Feb 20207:00 amRNSHalf-year Report
20th Feb 202011:12 amRNSIssue of Equity
18th Feb 20209:51 amRNSIssue of Equity
30th Jan 20203:43 pmRNSIssue of Equity
15th Jan 20207:00 amRNSInvestor results presentation
14th Jan 20201:09 pmRNSIssue of Equity
17th Dec 201911:01 amRNSResult of AGM
17th Dec 20197:00 amRNSAGM Statement and notice of results
4th Dec 20199:30 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.